Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 2005

View Archived Issues

Schering-Plough highlights first quarter developments

G-207 studied in malignant glioma

NX-1207 shows long-term efficacy in improving the symptoms of BPH

Phase II study investigates ginger for CINV

Dosing begins in phase I trial of Hedgehog antagonist for basal cell carcinoma

Harnal D launched in Japan

Chugai subsidiary renamed

FDA extends action date for SomatoKine NDA

MicroRNAs: potential novel human oncogenes

Further study required for Sativex approval in U.K.

IPI-504 studied in relapsed and relapsed refractory multiple myeloma

Spotlight on PTSD

Phase I results discussed for Sinovac's SARS vaccine

Fast track designation for Laszarin for heart failure in diabetes patients

NIP-004: Novel thrombopoietin mimetic small-molecule compound

Combi-molecule targets Bcr-Abl kinase and damages DNA

Lyrica approved as add-on treatment for partial onset seizures

Zmax single-dose antibiotic receives FDA approval

Long-term effects reported for febuxostat in hyperuricemia and gout

Clazosentan acts as a potent competitive ETA receptor antagonist

NVP-AEW-541 studied for treatment of musculoskeletal tumors

Recent patent discloses novel immunosuppressive agents

Iloprost and bosentan reduce mortality in PPH patients waiting for a transplant

Novel therapeutics for cardiovascular diseases reported in recent patents

Potassium channel blockers for glaucoma, etc., emerge from Merck & Co. research

MCI-196 decreases serum phosphate and cholesterol levels of hemodialysis patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...